Use of long-acting ß2ar agonist in preparation of drugs for treating cancers
AssigneeHong Kong Sxmeterol Pharmaceutical Co., Limited
InventorsHua GAO, Junxian MA
Life of this patent
Estimating the term…
Abstract
Disclosed in the present invention is use of a long-acting β2AR agonist or pharmaceutically acceptable salts thereof in preparation of drugs for treating cancer. The long-acting β2AR agonist of the present invention can target β2AR on the surface of a cancer cell membrane as a single functional molecular target, and perform targeted inhibition on a self-renewal capability of cancer stem cells to exert a function of inhibiting cancer initiation and progression. Therefore, the β2AR agonist may be clinically used for treating cancer. In addition, as a repurposed drug, the long-acting β2AR agonist may exhibit enhanced clinical translation potential and druggability.
Claims11
A method of treating cancer, the method comprising administering to a subject a therapeutically effective amount of a long-acting β2AR agonist or pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.